Boston Biomedical announces the Grand Opening of its Cambridge Headquarters
CAMBRIDGE, Mass., July 12, 2013 /PRNewswire/ -- Boston Biomedical, Inc. this week celebrated the relocation of its headquarters to Cambridge, Massachusetts with a grand opening ceremony. Academic, business and government leaders, as well as executives from Dainippon Sumitomo Pharma Co., Ltd. (DSP), the parent company of BBI, joined the celebration.
"We are pleased to celebrate the opening of our new facility, which will greatly expand the efforts of the Boston Biomedical team in our quest for better therapies for cancer," said Dr. Chiang J. Li, M.D. FACP, the founder, president, and CEO of Boston Biomedical, Inc. "With this facility, and the support of DSP, we intend to make significant progress in translating exciting discoveries in cancer stem cell science into innovative therapeutics for cancer patients."
Boston Biomedical is focusing on developing the next generation of targeted cancer therapeutics, and is recognized as an industry leader in the creation of drugs designed to target cancer stem cells (CSC) which are highly malignant and considered to be fundamentally responsible for cancer growth, recurrence, drug-resistance and metastasis.
"Investing in education, innovation and infrastructure is a winning growth strategy for Massachusetts and is the reason we lead the world in life sciences," said Governor Deval Patrick. "We welcome Boston Biomedical's new facility in Cambridge and thank them for their commitment to growing and creating jobs here."
"We chose Cambridge as the location for Boston Biomedical's new headquarters to capitalize on the easy access to leading-edge scientific research and technology developed by the surrounding world-class universities and research institutes," said Mr. Masayo Tada, President and CEO of DSP, and Chairman of Boston Biomedical, Inc. The new, 64,000-square-foot facility is located at 640 Memorial Drive, a historical landmark situated at the epicenter of the region's life science and technology clusters.
"Despite the great advances in the field of oncology over the past few decades, cancer is the second-most common cause of death in the nation," said Susan Windham-Bannister, Ph.D., President & CEO of the Massachusetts Life Sciences Center, the quasi-public agency tasked with implementing the state's 10-year, $1-billion Life Sciences Initiative. "We look forward to Boston Biomedical's continued R&D efforts here in Massachusetts, as they make advances that may hold promise for cancer patients across the world. We also welcome the increased presence of DSP in the Massachusetts life sciences community, part of a growing relationship between the life sciences clusters in Massachusetts and Japan."
With a new state-of-the-art facility and support from DSP, Boston Biomedical aims to continue to leverage its scientific excellence and leadership in order to advance the development of novel cancer therapeutics.
About Boston Biomedical, Inc.
Boston Biomedical, Inc. (Founder, President, CEO and CMO: Chiang J. Li, M.D. FACP) was founded in November, 2006 and is fully owned by Dainippon Sumitomo Pharma Co., Ltd. Boston Biomedical is focused on the research and development of novel cancer therapeutics, and has developed a world-leading product pipeline targeting cancer stem cells. Boston Biomedical's innovation in drug discovery has received a number of recognitions and awards in the United States, including sole recipient of the Frost & Sullivan 2010 North American Drug Discovery Technology Innovation of the Year Award, 2011 Biotech Pioneer Award (Alexandria Oncology Summit). Boston Biomedical is headquartered in Cambridge, Massachusetts, USA. Additional information about the company and its product pipeline can be found at bostonbiomedical.com.
About Dainippon Sumitomo Pharma Co., Ltd. (DSP)
Dainippon Sumitomo Pharma Co., Ltd. (DSP) is a multi-billion dollar, top-ten listed, pharmaceutical company in Japan with a diverse portfolio of pharmaceutical products. DSP aims to produce innovative pharmaceutical products in the Psychiatry & Neurology field and Oncology field, which are designated as focus therapeutic areas. The DSP Group is enhancing its presence in oncology with the aim of making it a future core business area next to CNS. DSP has more than 7,000 employees worldwide. Additional information about DSP is available through its corporate website at http://www.ds-pharma.com/.
About DSP Global Oncology R&D
In September 2012 the DSP Cancer Institute was established in Japan as an organization independent of the Research Division under direct control of the President, Masayo Tada. In charge of the DSP Cancer Institute is Chiang J. Li MD FACP, the Head of Global Oncology for DSP Group. DSP aims to continually create leading-edge, breakthrough products under the strong collaboration between BBI and the DSP Cancer Institute.
SOURCE Boston Biomedical, Inc.